Xilio Therapeutics, Inc. Payments of Stock Issuance Costs
Xilio Therapeutics, Inc. (XLO) reported Payments of Stock Issuance Costs of $1.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-12
- Xilio Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- Xilio Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $1.55M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.55M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.55M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |